Broadfin Capital, LLC
CIK 1511901 · last filed 2022-03-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
REPH price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
NEW YORK, NY 10022
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AVADEL PHARMACEUTICALS PLC (AVDL) Delisted | Director | 3,130,573 | $21.64 | $67.75M | $0 | 1 | 2019-08-09 |
| NOVELION THERAPEUTICS INC. (NVLN) Delisted | Director | — | — | — | $0 | 2 | 2018-03-19 |
| Societal CDMO, Inc. (REPH) Delisted | 10%+ Owner | 2,236,025 | $2.09 | $4.67M | -$1.21M | 5 | 2018-03-15 |
| ARATANA THERAPEUTICS, INC. (PETX) Delisted | 10%+ Owner | 4,776,834 | — | — | -$15.23M | 1 | 2017-12-01 |
| Corium International, Inc. (CORI) Delisted | 10%+ Owner | 4,068,626 | — | — | -$12.18M | 2 | 2017-11-03 |
| PROGENICS PHARMACEUTICALS INC (PGNX) Delisted | 10%+ Owner | 7,147,269 | — | — | -$17.46M | 2 | 2017-02-15 |
| Aegerion Pharmaceuticals, Inc. (AEGR) Delisted | 10%+ Owner | 4,210,291 | — | — | $2.69M | 3 | 2016-09-12 |
Recent Filings · Page 2 of 3
26 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-03-19 | NOVELION THERAPEUTICS INC. (NVLN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-03-15 | Societal CDMO, Inc. (REPH) Delisted | Sell (S) | −600,000 | -$6.04M | EDGAR |
| 2017-12-14 | Societal CDMO, Inc. (REPH) Delisted | Sell (S) | −279,711 | -$2.76M | EDGAR |
| 2017-12-07 | Societal CDMO, Inc. (REPH) Delisted | Sell (S) | −300,000 | -$3.00M | EDGAR |
| 2017-12-01 | ARATANA THERAPEUTICS, INC. (PETX) Delisted | Sell (S) | −2,671,548 | -$15.23M | EDGAR |
| 2017-11-03 | Corium International, Inc. (CORI) Delisted | Sell (S) | −450,000 | -$4.97M | EDGAR |
| 2017-10-06 | Corium International, Inc. (CORI) Delisted | Sell (S) | −654,300 | -$7.20M | EDGAR |
| 2017-02-15 | PROGENICS PHARMACEUTICALS INC (PGNX) Delisted | Sell (S) | −1,807,800 | -$17.46M | EDGAR |
| 2017-01-13 | PROGENICS PHARMACEUTICALS INC (PGNX) Delisted | Disp (D) | −3,000,000 | -$26.85M | EDGAR |
| 2016-12-27 | NOVELION THERAPEUTICS INC. (NVLN) Delisted | Gift (G) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.